FDA just approved GSK's new asthma shot, Exdensur

Technology Dec 17, 2025

Big news for people with severe asthma: the FDA has given the green light to GSK's Exdensur, a treatment for ages 12 and up.
What's cool? Instead of needing shots every month (or even more often), Exdensur only needs to be taken twice a year—making life way simpler for patients.

Why this matters for GSK (and what's next)

This approval is a big win for GSK as they try to keep up with competitors and deal with expiring patents.
The drug launches as Luke Miels prepares to take over as CEO in early 2026 and will go head-to-head with treatments like Dupixent.
While Exdensur wasn't cleared yet for another condition (chronic rhinosinusitis with nasal polyps), GSK is still working on that front—and aiming high with their revenue goals by 2031.